Summary Macrophage inflammatory protein-la (MIP-la) is an inhibitor of stem cell proliferation affording protection against damage from agents that express their cytotoxicity specifically in the DNA synthesis phase of the cell cycle. Its ability also to modify the self-renewal capacity of the regenerating cells is now shown to improve and maintain haemopoietic recovery following therapy (sublethal irradiation) whose cytotoxic damage is not limited solely to the DNA-S phase of this cycle. Such non-cell cycle-active cytotoxic agents are used clinically in repeated treatment regimens, which are often limited or terminated because of accumulating haemopoietic damage. BB-10010, a non-aggregating variant of MIP-la, was administered as a continuous dose (1600 ,ug kg-l 24 h-') via a subcutaneously implanted pump over a period of 7 days. A dose of 4.5 Gy totalbody y-rays was given 3-4 h after implantation. Day 8 and 12 spleen colony-forming units (CFU-S) were assayed on days 1, 7 and 14 after irradiation. This cycle of treatment was repeated four times (total 56 days), and on day 14 of the last two cycles the marrow-repopulating ability (MRA) was also measured. In the control bone marrow (no BB-10010) CFU-S fell to < 1% of normal within 1 day of irradiation and recovered to 40% at 14 days. Repeated treatments increased the level of damage, and after four cycles CFU-S recovered to only 10% of normal. BB-10010 afforded little benefit in the first treatment cycle, but by the end of the fourth cycle CFU-S still recovered to 35% of normal. MRA was reduced to 7% of normal by the irradiation protocolabout half that maintained by BB-10010 protection. We conclude that BB-10010 (MIP-la) reduces the degree of accumulated haemopoietic stem cell damage following repeated non-cell cycle-specific cytotoxic insults -a principle which should be valuable in repeated clinical cytotoxic therapy regimens.
Macrophage inflammatory protein-lbx (MIP-loa) has been recognised as a haemopoietic stem cell proliferation inhibitor by its capactiy to protect multipotent progenitor cells from cytotoxic agents, which are effective against cells specifically in DNA synthesis, both in vitro and in vivo (Lord et al., 1976; 1992 Wright and Lord, 1977; Graham et al., 1990; Clements et al., 1992; Dunlop et al., 1992; Cooper et al., 1994) . In one series of experiments in which MIP-lax was given in vivo to protect haemopoietic spleen colony-forming units (CFU-S) (Till and McCulloch, 1962) from the effects of hydroxyurea (HU), the subsequent recovery rate of the (partially) protected population appeared to be higher than in the control (HU-treated) population . This was complementary to an earlier observation that the partially purified inhibitor enhanced the generation of haemopoietic cells in long-term bone marrow cultures (Lord et al., 1987) . Furthermore, it led to the suggestion that, in addition to its capacity to block the progression of progenitor cells into DNA synthesis, MIP-la had effects also on the self-renewal and differentiation capacity of the surviving multipotent progenitor cell population . This enhanced rate of recovery of the CFU-S population has recently been confirmed and direct measurements showed the self-renewal capacity of the CFU-S population surviving HU treatment to be enhanced by MIP-la given in vivo (Lord, 1995) .
These observations together suggested that the clinical value of MIP-la need not be limited to protection of haemopoietic stem cells from cytotoxic agents which specifically damage the DNA synthesis phase of the cell cycle. CFU-S populations depleted by non-cell cycle-specific treatments, but exposed to MIP-la, might emerge with a higher self-renewal capacity, thus restocking the stem cell compartments more efficiently and making them less susceptible to the accumulating damage incurred by the repeated treatment cycles commonly used in chemotherapeutic regimens.
Repeated sublethal doses of irradiation result in a longterm accumulation of damage such that recovery of the CFU-S population is successively more impaired, i.e. the plateau level of CFU-S recovery is lower with each successive cycle of radiation (Hendry and Lajtha, 1972 
CFU-S assays
Haemopoietic spleen colony-forming units (CFU-S) were assayed as previously described (Lord, 1993) . Briefly, mice (groups of 20) were irradiated (whole body) with 15.25 Gy 'Co y-rays (0.95 Gy h-1). They were then injected intravenously with 0.2 ml of a freshly prepared suspension of bone marrow cells from mice treated as described above. Eight days (ten mice) and 12 days (ten mice) later the recipient mice were killed. Their spleens were excised, fixed and the macroscopic colonies counted using a dissecting microscope.
Marrow repopulating ability assays (MRA) The MRA was measured as the generation of 12 days CFU-S during 13 days' growth in the marrow by an extension of the CFU-S assay (see Lord, 1993 for details), on day 14 of the third and fourth treatment cycles. An extra five irradiated (primary) recipients were injected with the bone marrow suspension. After 13 days their femora were removed. Bone marrow suspensions were made and assayed for CFU-S12 in secondary groups of ten irradiated recipients as described Three secondary assays were carried out for each primary recipient bone marrow pool for which p = 10, 20 and 40. In these experiments q =50 or 100.
Protocols
(1) Groups of three mice were implanted subcutaneously with mini-osmotic pumps delivering BB-10010 (40 ug per 24 h period for 7 days) or its vehicle, phosphatebuffered saline (PBS). Three to four hours later they were exposed (whole body) to 4.5 Gy y-rays from a caesium-137 source (dose rate 2.5 Gy min-') and after 7 days the spent pumps were removed. Groups of mice were killed at 1, 7 and 14 days after irradiation and their femora and spleens removed. Cell suspensions were made in Fischer's medium from the bone marrow and spleen (Lord 1993 for details), counted and assayed for day 8 (CFU-S8) and day 12 (CFU-S2) colony-forming units. The cellular concentrations of the inoculation suspensions were adjusted so that 0.2 ml injected (Table II) . A similar pattern of loss and recovery was evident in the BB-10010-treated mice and at the end of each of the four treatment cycles, the average marrow cellularity was 29% higher than in the controls (P= 0.002). In the first treatment cycle, bone marrow CFU-S were reduced to less than 1% of their normal levels and in 14 days, CFU-S8 and CFU-S12 recovered to 40% and 20% respectively (Figure 1 ). BB-10010 induced a small, but non-significant increase in the recovery rate of both CFU-S8 and CFU-S2. Repeated cycles of irradiation increased the damage to CFU-S in the untreated marrows. One day after irradiation, CFU-S survival levels were successively lower (Figures 1 and  2 ) as were the 14 day recovery levels (Figures 1 and 3) , CFU-S8 reaching only 10% and CFU-S12 6% of their starting levels after the fourth cycle of treatment. Intrinsic errors in measuring the very low CFU-S numbers 1 day after irradiation are unavoidably high. Figure 2 , however, indicates that BB-10010 had little effect in the first cycle, but after the fourth cycle of treatment, about twice as many CFU-S survived (Figures 1 and 2 for CFU-S8 and CFU-S12, P<0 .01 in the fourth cycle). The degree of recovery was maintained with each successive treatment cycle (Figures 1  and 3, P<0 .001 over cycles 2-4 for CFU-S8 and CFU-S12) and at the end of the fourth treatment cycle both CFU-S8 and CFU-Sl2 were about 35% of normal levels in the BB-10010-treated mice compared with less than 10% without BB-10010.
At the end of each treatment cycle, splenic CFU-S8 had recovered equally well with or without BB-10010 but for the most part, maximum recovery was achieved earlier (by 7 days) with BB-10010 (Figure 4 ). This was true also for CFU-S12 which in the non-protected mice were still on the recovery curve at 14 days in the second, third and fourth cycles.
Marrow repopulating ability is normally recorded for these mice at about 105 per femur or 500 per 105 marrow cells (Lord and Woolford, 1993) . Thirteen day recovery marrow in the third and fourth cycles of sublethal irradiation yielded an MRA of only 6500-7300 per femur at concentrations less than 10% of normal (Table III) . Treatment with BB-10010 yielded an MRA of 26 600 (P<0.001) after the third cycle and 11 206 (P<0.02) after the fourth cycle of irradiation (Table III) . The corresponding increase in cellular concentration of MRA cells of 1.3-3 times reflected the increase previously reported in self-renewal capacity of the stem cell populations following MIP-la treatment (Lord, 1995) .
Over two cycles of irradiation treatment, CFU-S in mice receiving PBS alone recovered to 730 per femur (Table IV) . Pumps delivering BB-10010 during and after irradiation increased this to 1270 (P=0.01). Less advantage was obtained when BB-10010 dosing was delayed by 1 day (960 CFU-S per femur, NS), and none at all when dosing in the second half of each radiation cycle.
Discussion
It is a common feature associated with repeated cycles of cytotoxic therapies that accumulating damage to the haemopoietic tissue often results in delays to the administration of the later treatments; indeed possibly to the curtailment of further cycles. Experimentally, it is known that repeated doses of sublethal irradiation also result in accumulating damage to the spleen colony-forming units (Hendry et al., 1974) . We chose, therefore, to use irradiation as a convenient model to test the potential of BB-10010 to maintain recovery of the stem cell populations. The 4 x 4.5 Gy irradiation model described by Hendry et al. (1974) was adopted, although the repeat interval was shortened to 14 days. This was to ensure suboptimally recovered haemopoietic tissue and, therefore, avoid any likelihood of masking beneficial effects of BB-10010. The progressively lower 1 day survivals and 14 day recovery peaks with increasing cycle number confirm that haemopoietic damage was accumulated through the experiment (Figures 2  and 3 ). In addition, and in spite of their somewhat greater radioresistance (Meijne et al., 1991; Ploemacher et al., 1992) , the marrow repopulating cells also demonstrated significant accrued damage (Table II) .
It has previously been shown that protection from hydroxyurea damage, using MIP-la, results in a more rapid recovery of the multipotent progenitor populations that are relatively enriched in the better self-renewing cells (Lord, 1995) Lord and Woolford (1993) . Current data are mean values+s.e. strated that the equivalent in vitro long-term culture-initiating cells were maintained better in cultures treated with MIP-lcI (in combination with IL-3). This modulation in favour of self-renewal potential effectively reduces differentiation potential. It does not necessarily adversely affect the production of differentiated cells, however. Indeed, the increased reserves of 'stem' cells generated by increased selfrenewal, can provide a pool that is more than adequate to compensate the reduced differentiation rate. We reasoned, therefore, that recovery from sublethal doses of irradiation could be similarly enhanced by the presence of MIP-lac, during and after the period of irradiation.
The results presented here indicate that this rationale was sound. BB-10010 gave little, if any, protection from the first dose of irradiation but the better recovery characteristics, particularly in respect of the highly enriched MRA, ensured that the second and subsequent irradiations caused progressively less initial damage (Figure 2 ) and that the recovery patterns did not significantly deteriorate (Figure 3 ). In these experiments, our primary aim was to assess the ability of BB-10010 to support a better quality haemopoietic progenitor cell component in the bone marrow and spleen. The design of the experiments, therefore, was such that simultaneous recording of peripheral blood cell levels was not practical. Preliminary experiments (unpublished data) with cyclophosphamide and 5-fluorouracil (5-FU) suggest that neutrophil production is promoted by 1-2 days, supporting the observations of Dunlop et al. (1992) . These experiments demonstrated a fuller and earlier recovery of the progenitor populations with full restoration of the haemopoietic, nucleated cell populations and consistent with conditions for earlier recovery of the mature cell products. The very early recovery of the splenic CFU-S population (Figure 4) would be expected to contribute to such a process. However, the role of the spleen is not clear. It has to be recognised that, relative to total haemopoiesis, the splenic contribution is small and, in a comparable human protocol, would probably play no part.
In these experiments, BB-10010 was supplied continuously for 7 days of each cycle. At this stage, we have no evidence 1022 that this length of time is necessary, nor even that the MIPla remains active under these conditions for the whole 7 days. The timing and administration protocols, therefore, remain the subject of further investigation. While it is clear that this type of protocol is a practical scenario, the mechanisms by which MIP-la is promoting recovery are not clear. The demonstration that MIP-lcx contributes to a better maintenance of primitive haemopoietic stem cells (Verfaillie et al., 1994) , that a CFU-S population regenerating after exposure to MIP-la has a higher selfrenewal capacity (Lord, 1995) and supported by a recent observation that recovery is enhanced following cyclophosphamide (a non-S-phase-specific cytotoxic agent) treatment (Parker et al., 1995) , all suggest that recovery kinetics are improved by MIP-la. It is not clear whether MIP-la (BB-10010 in this instance) has any direct radioprotective effect. Initial depopulation of CFU-S (1 day nadir, cycle 1, Figure 2) suggests not. However, those recovery characteristics were clearly improved by the presence of BB-10010 at the time of irradiation (Table IV) . Delay of exposure to BB-10010 until 1 day after irradiation ameliorated the recovery significantly and when administered during the later stages of recovery, it gave no beneficial advantage (Table IV) .
In summary, we conclude that the cumulative effects of non-cycle-specific cytotoxic therapies on normal haemopoiesis can be ameliorated by the administration of BB-10010/MIPla during, and in the aftermath of, such treatments. These experiments should, therefore, provide a base for protection experiments and treatments with other clinically appropriate cyclical therapies using cytotoxic alkylating agents. Ultimately, they should be directly transferable to appropriate clinical scenarios in the treatment of cancer.
